{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:03:10Z","timestamp":1787317390840,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtos.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:05:23Z","timestamp":1759341923000},"page":"324-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Interdisciplinary management of belantamab mafodotin-associated ocular toxicity in clinical practice"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8315-0001","authenticated-orcid":false,"given":"Mattan","family":"Arazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Wattad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirit","family":"Agay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina S.","family":"Barequet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jtos.2025.09.003_bib1","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtos.2025.09.003_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jtos.2025.09.003_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"23","key":"10.1016\/j.jtos.2025.09.003_bib4","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single\u2010agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM\u20102 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jtos.2025.09.003_bib5","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody\u2013drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtos.2025.09.003_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: Neuropathy studied with confocal microscopy","volume":"242","author":"Aschauer","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.09.003_bib7","doi-asserted-by":"crossref","unstructured":"Gallin V, N\u00f6lle B, Schub N, Roider J. Visualization of keratopathy associated with the antibody\u2013drug conjugate belantamab mafodotin using infrared imaging in patients with multiple myeloma. Cornea. Published online June 18, 2024. doi:10.1097\/ICO.0000000000003596.","DOI":"10.1097\/ICO.0000000000003596"},{"key":"10.1016\/j.jtos.2025.09.003_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jtos.2025.09.003_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: multi\u2010institutional <scp>real\u2010life<\/scp> experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtos.2025.09.003_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin\u2010induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jtos.2025.09.003_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jtos.2025.09.003_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: multi\u2010institutional <scp>real\u2010life<\/scp> experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jtos.2025.09.003_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"21","key":"10.1016\/j.jtos.2025.09.003_bib14","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: Belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtos.2025.09.003_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-025-01212-0","article-title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","volume":"15","author":"Mukhopadhyay","year":"2025","journal-title":"Blood Cancer J"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:56:05Z","timestamp":1764755765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012425001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"alternative-id":["S1542012425001132"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2025.09.003","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interdisciplinary management of belantamab mafodotin-associated ocular toxicity in clinical practice","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}